Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Triamcinolone
Drug ID BADD_D02271
Description Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis.[L8255] Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain,[L8264] or first line as a topical treatment of corticosteroid responsive dermatoses.[L8249] Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957.[L8243] In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval[L38973] - for the treatment of patients with macular edema associated with uveitis.[L38963]
Indications and Usage For the treatment of perennial and seasonal allergic rhinitis.
Marketing Status Discontinued
ATC Code A01AC01; C05AA12; D07AB09; D07XB02; H02AB08; R01AD11; R03BA06; S01BA05
DrugBank ID DB00620
KEGG ID D00385
MeSH ID D014221
PubChem ID 31307
TTD Drug ID D03BLF
NDC Product Code 22552-0003; 46439-8701; 38779-0051; 51927-1049
Synonyms Triamcinolone | Volon | Aristocort
Chemical Information
Molecular Formula C21H27FO6
CAS Registry Number 124-94-7
SMILES CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Malignant melanomaSerotransferrinP02787T026173015380; 2737997; 3919942; 6850583; 2788234; 2788497; 3297308; 6424929; 2439521; 6454570; 3049518; 6983291; 8826092; 6273246
Malignant melanomaInsulinP01308T828413015380; 2737997; 3919942; 6850583; 2788234; 2788497; 3297308; 6424929; 2439521; 6454570; 3049518; 6983291; 8826092; 6273246
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Calcinosis08.03.04.002--Not Available
Cardiac arrest02.03.04.001--
Cardiac failure congestive02.05.01.002--Not Available
Cardiomegaly02.04.02.001--Not Available
Cataract06.06.01.0010.000126%
Cataract subcapsular06.06.01.002--Not Available
Cellulitis23.09.01.001; 11.02.01.0010.000190%Not Available
Chills15.05.03.016; 08.01.09.0010.000190%
Colitis ulcerative10.02.01.004; 07.08.01.0050.000316%Not Available
Confusional state17.02.03.005; 19.13.01.001--
Conjunctivitis11.01.06.012; 06.04.01.002--
Cough22.02.03.001--
Crohn's disease10.02.01.005; 07.08.01.0150.000190%Not Available
Cushing's syndrome19.07.03.002; 14.11.01.007; 05.01.01.001; 24.08.04.001--Not Available
Cushingoid24.08.02.004; 19.07.03.001; 14.11.01.006; 05.01.01.002--
Depression19.15.01.001--
Dermatitis23.03.04.0020.000253%Not Available
Dermatitis acneiform23.02.01.004--
Dermatitis atopic10.01.04.004; 23.03.04.016--Not Available
Dermatitis bullous23.03.01.002--
Dermatitis contact23.03.04.004; 12.03.01.040; 10.01.01.003--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diarrhoea07.02.01.001--
Diplegia17.01.04.015--Not Available
Diplopia06.02.06.002; 17.17.01.0050.000126%Not Available
Discomfort08.01.08.003--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.000696%
Drug hypersensitivity10.01.01.001--Not Available
Dry mouth07.06.01.0020.000126%
Dysgeusia17.02.07.003; 07.14.03.001--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 9 Pages